Clinical trials: Mask
Cataract
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
- Trial name
- NCT05550350
- Testing
- Dexycu
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
To investigate whether the IOP lowering efficacy of STN1012600 ophthalmic solution 0.002% is non-inferior to that of latanoprost 0.005% in subjects with POAG or OHT after treatment for 4 weeks.
- Trial name
- NCT05495061
- Testing
- STN1012600 ophthalmic solution 0.002%, Latanoprost ophthalmic solution 0.005%
- Where
- 44 sites in Japan
- Volunteers
- 325 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Cystoid Macular Edema, Uveitis
Study to Treat Uveitis Associated Macular Edema
The purpose of this study is to determine whether denufosol tetrasodium (INS37217) Intravitreal Injection is well tolerated and has the potential to treat uveitis associated macular edema.
- Trial name
- NCT00114062
- Testing
- denufosol tetrasodium (INS37217) Intravitreal Injection
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Trial name
- NCT07441642
- Testing
- FWY003
- Where
- 59 sites in United States, Argentina and 16 more
- Volunteers
- 272 people
- Sponsor
- Novartis Pharmaceuticals
Retinitis Pigmentosa (RP), Usher Syndrome Type 2
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- LUNA (NCT06627179)
- Testing
- Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention
- Where
- 26 sites in United States, Belgium and 8 more
- Volunteers
- 81 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease
Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)
The objective of this study is to evaluate the chronic safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs of dry eye disease (DED).
- Trial name
- NCT03873246
- Testing
- OC-01 0.1% 0.6 mg/ml, OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
- Where
- Mexico
- Volunteers
- 123 people
- Sponsor
- Oyster Point Pharma, Inc.
Corneal Epithelial Disorders
Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02104388
- Testing
- SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic Solution
- Where
- 17 sites in United States
- Volunteers
- 69 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Neovascular Age-Related Macular Degeneration
Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
The purpose of this study is to assess the systemic pharmacokinetics (PK) and safety of 2 different doses of brolucizumab (3 milligrams (mg)/50 microliters (μL) and 6 mg/50 μL) when administered at 4-week intervals for a total of…
- Trial name
- NCT02507388
- Testing
- Brolucizumab 3 mg/50 μL, Brolucizumab 6 mg/50 μL
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Ocular Discomfort
A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
The primary objective of this exploratory study is to assess preliminary efficacy and safety of rhNGF when administered as eye drops to patients after cataract and refractive surgery.
- Trial name
- NCT03035864
- Testing
- rhNGF, Vehicle
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Dompé Farmaceutici S.p.A
Thyroid Eye Disease
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses.
- Trial name
- NCT06401044
- Testing
- AMG 732
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Amgen
Eyelash Hypotrichosis
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes following chemotherapy treatment.
- Trial name
- NCT01391286
- Testing
- bimatoprost solution 0.03%, bimatoprost vehicle solution
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Allergan
Cataract
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
The goal of this clinical trial is to learn if MELT-300 works on procedural sedation in adult participants undergoing cataract extraction with lens replacement (CELR). It will also learn about the safety of MELT-300.
- Trial name
- NCT06383273
- Testing
- MELT-300 sublingual tablet, Midalozam sublingual tablet
- Where
- 12 sites in United States
- Volunteers
- 528 people
- Sponsor
- Melt Pharmaceuticals
Myopia
CHAMP: Study of NVK-002 in Children With Myopia
Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period.
- Trial name
- NCT03350620
- Testing
- NVK-002 Concentration 1, NVK-002 Concentration 2
- Where
- 26 sites in United States, Hungary and 4 more
- Volunteers
- 670 people
- Sponsor
- Vyluma, Inc.
Obstructive Sleep Apnea
Evaluation of the Toffee Nasal and Toffee Nasal Pillows Mask in Home, USA, 2022
This clinical investigation is designed to assess the F\&P Toffee Nasal and Toffee Nasal Pillows masks in home for use during PAP therapy delivery.
- Trial name
- NCT05496062
- Testing
- F&P Toffee Nasal and Toffee Nasal Pillows Masks
- Where
- 2 sites in United States
- Volunteers
- 91 people
- Sponsor
- Fisher and Paykel Healthcare
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
- Trial name
- REVEAL-1 (NCT06625411)
- Testing
- VRDN-003
- Where
- 48 sites in United States, Germany and 3 more
- Volunteers
- 132 people
- Sponsor
- Viridian Therapeutics, Inc.
Uveitis, Anterior, Panuveitis
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
- Trial name
- LUMINATE (NCT00404885)
- Testing
- LX211
- Where
- 30 sites in United States, Austria and 5 more
- Volunteers
- 108 people
- Sponsor
- Lux Biosciences, Inc.
Dry Eye Disease (DED)
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
- Trial name
- PREDICT-1 (NCT07548632)
- Testing
- Artificial Tear Run-in, licaminlimab, Vehicle of licaminlimab
- Where
- 14 sites in United States
- Volunteers
- 160 people
- Sponsor
- Oculis
Visual Acuity, Geographic Atrophy
A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy
The purpose of this study is to evaluate the safety and performance profile of the suprachoroidal surgical approach and the Delivery System.
- Conditions
- Visual Acuity, Geographic Atrophy, Macular Degeneration
- Trial name
- PRELUDE (NCT02659098)
- Testing
- CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Janssen Research & Development, LLC
Obstructive Sleep Apnea
A Phase II Pilot Study of the Trillium Full Face Mask
This will be a single-center, open-label randomized crossover design pilot study to evaluate the clinical safety, clinical performance, and clinical benefit of the Trillium full face mask
- Trial name
- NCT06932055
- Testing
- Trillium Full Face Mask, AirFit F20
- Volunteers
- 40 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Primary Open Angle Glaucoma, Ocular Hypertension
Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
This randomized dose-ranging study will evaluate the safety, tolerability, and preliminary efficacy (reduction in intraocular pressure) of multiple dose levels of ATS907, vehicle, or latanoprost in subjects with primary open…
- Trial name
- NCT01520116
- Testing
- Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Altheos, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.